Brooklyn ImmunoTherapeutics Total Current Liabilities

Brooklyn ImmunoTherapeutics (BTX) currently reports a total current liabilities of $10M as of December 2025. In the prior-year period, the figure was $0. Use the charts on this page to explore Brooklyn ImmunoTherapeutics's total current liabilities history and peer comparisons.

Brooklyn ImmunoTherapeutics's total current liabilities changed from $0 to $10M (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Brooklyn ImmunoTherapeutics reported $10M in total current liabilities as of December 2025. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $10M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Brooklyn ImmunoTherapeutics, and consider following BTX for alerts when major investors trade the stock.

Brooklyn ImmunoTherapeutics is classified in the Telecommunications sector. On total current liabilities, it currently shows $10M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing BTX with unrelated industries.